Join
Live feed
·
PRReleasevia Quantisnow
Mereo BioPharma Group plc logo

Mereo BioPharma Reports Interim Data from ACTIVATE Phase 1b/2 Open Label Study of etigilimab Anti-TIGIT Antibody in combination with Nivolumab in Solid Tumors

ByQuantisnow·Wall Street's wire, on your screen.
MREO· Mereo BioPharma Group plc
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track MREO (Mereo BioPharma Group plc) and more on Quantisnow.